Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study.
Regino P Gonzalez-PeraltaStefan WirthRobert H SquiresFrauke MutschlerThomas LangMałgorzata PawłowskaWojciech SluzewskiEwa Majda-StanisławskaBjorn FischlerWilliam F BalistreriMaureen M JonasNiviann BlondetPhilip RosenthalRohit L LoombaRene RomeroAnjana GrandhiPatricia CastronuovoLuzelena CaroLihong DuDaniel I S RosenbloomBarbara A HaberPublished in: Hepatology communications (2023)
Pediatric EBR/GZR pharmacokinetic models were successfully developed based on complex adult population pharmacokinetic models. At appropriate age-related doses, EBR/GZR is safe and effective in pediatric and adolescent participants with HCV infection.